EssilorLuxottica Acquires RetinAI to Bolster Its Med-Tech Strategy
EssilorLuxottica announces the acquisition of Ikerian AG, operating under the brand RetinAI, which specializes in AI and data science-based medical technologies for the optical sector.
Strengthening Med-Tech Capabilities
EssilorLuxottica has announced the acquisition of Ikerian AG, which operates under the brand RetinAI. RetinAI is an active company in the field of medical technologies, specializing in artificial intelligence (AI) and data management for the optical sector. The acquisition aims to strengthen the group's med-tech strategy by integrating advanced software based on machine learning and computer vision. These technologies aim to make clinical, research, and pharmaceutical processes more efficient. According to EssilorLuxottica, RetinAI enables the development of more accurate AI-based clinical solutions, contributing to improved quality of care and patient experience.
Advanced Solution Development
RetinAI focuses on developing cutting-edge solutions capable of collecting, processing, and analyzing large amounts of retinal images and biometric data. Its main platform, RetinAI Discovery, has received FDA approval through the 510(k) procedure and is CE certified. It uses AI models to monitor the progression of diseases such as age-related macular degeneration, diabetic retinopathy, and glaucoma, thus enabling rapid diagnostics and targeted interventions. Furthermore, RetinAI collaborates with pharmaceutical companies and research institutes to accelerate clinical trials and the development of new drugs using proprietary real-world data.
Enhancing Integrated Digital Care Experience
The President and CEO of EssilorLuxottica, Francesco Milleri, commented that the acquisition of RetinAI is part of an effort to build a more complete, integrated, and digital care experience. With the analytical power of AI, EssilorLuxottica hopes to transform clinical data into insights that allow for quicker and more accurate diagnostics, while more effectively monitoring the progression of various pathologies. Carlos Ciller, President and CEO of RetinAI, added that this acquisition marks an important new chapter for the team and technology of RetinAI, enabling them to realize their vision on a global scale thanks to the presence of EssilorLuxottica.
